James M. Frates - 30 Sep 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
30 Sep 2025
Net transactions value
-$154,650
Form type
4
Filing time
02 Oct 2025, 16:15:12 UTC
Previous filing
31 Jul 2025
Next filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FRATES JAMES M Chief Financial Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE /s/ Joshua B. Cohen, as Attorney in Fact 02 Oct 2025 0001235598

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale $154,650 -10,558 -3.6% $14.65 280,430 30 Sep 2025 Direct F1, F2
holding AMLX Common Stock 15,459 30 Sep 2025 By Trust F3
holding AMLX Common Stock 11,072 30 Sep 2025 By Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F4 Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.